ClinicalTrials.gg
RecruitingNCT05587712MOONBEAMUpdated Nov 2, 2026

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

A Phase 2 interventional study of Sotatercept in Pulmonary Arterial Hypertension, sponsored by Merck Sharp & Dohme LLC. Recruiting at 35 sites in 12 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
1 Year to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing sotatercept in Pulmonary Arterial Hypertension — 7 open to participants now, 10 under way, 1 of them phase 3. sotatercept · Pulmonary Arterial Hypertension.

Planned enrollment
10th of 18
42 · median 44
Started
2023
with 2 others
Phase 2
7 of 18
3 open now
Registered
6th of 18
by date
Lead sponsor
7 of 18
Merck Sharp & Dohme LLC

Among the 18 studies testing sotatercept in Pulmonary Arterial Hypertension, this one is the 10th largest by planned enrollment, is one of 3 that started in 2023, is one of 7 in phase 2, and was the 6th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

7 of the 18 studies testing sotatercept in Pulmonary Arterial Hypertension are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About sotatercept

sotatercept: first FDA approval 2024 (WINREVAIR), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 1 Year to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing sotatercept in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to \<18 years of age with PAH World Health Organization (WHO) Group 1 on standard of care (SoC). There is no formal hypothesis.

03

Conditions studied

  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented, historic diagnostic right heart catheterization (RHC) any time before Screening confirming the diagnosis of PAH WHO Group 1 in any of the following subtypes:
  • Idiopathic pulmonary arterial hypertension (IPAH)
  • Heritable PAH
  • Drug/toxin-induced PAH
  • PAH associated with connective tissue disease
  • PAH-congenital heart disease (CHD) with shunt closure >6 months before Screening and subsequently confirmed by RHC before Screening
  • PAH with coincidental shunt.
  • Must be on a stable dose(s) of background PAH therapy (phosphdiesterase-5 (PDE5) inhibitors, endothelin receptor antagonists (ERAs), soluble guanylate cyclase stimulators (sGCS), or prostanoids [including subcutaneous and intravenous])
  • If male, agree to the following during the intervention period and for at least 16 weeks (112 days) after the last dose of study intervention:
  • Abstains from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agrees to remain abstinent or
  • Uses unless confirmed to be azoospermic (vasectomized or secondary to medical cause, documented from the site personnel's review of the participant's medical records, medical examination, or medical history interview) as detailed below:
  • Uses a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a woman of (WOCBP) who is not currently pregnant Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile-vaginal penetration.
  • If female, must be either not a WOCBP or use a contraceptive method that is highly effective or be abstinent from heterosexual intercourse during the intervention period and for at least 16 weeks (112 days) after the last dose of study intervention
  • If male, agrees to refrain from donating blood or sperm for the duration of the study and for 16 weeks (112 days) after the last dose of study intervention
  • If female, agrees to refrain from donating blood, eggs, or ovum for the duration of the study and for at least 16 weeks (112 days) after the last dose of study intervention

Exclusion criteria

Exclusion Criteria

  • History of left-sided heart disease, including valvular disease (eg, moderate or greater mitral or aortic regurgitation or stenosis), left ventricular outflow tract obstruction, and/or left heart failure (eg, restrictive or dilated cardiomyopathy)
  • Severe (as based on the opinion of the investigator) congenital or developmental abnormalities of the lung, thorax, and/or diaphragm
  • History of Eisenmenger syndrome, Potts shunt, or atrial septostomy
  • Unrepaired or residual cardiac shunt
  • Diagnosis of pulmonary veno-occlusive diseases, pulmonary capillary hemangiomatosis, or overt signs of capillary and/or venous involvement
  • PAH associated with portal hypertension
  • Known visceral (lung, liver, or brain) arteriovenous malformation(s)
  • History of full or partial pneumonectomy
  • Untreated more than mild obstructive sleep apnea
  • History of known pericardial constriction
  • Family history of sudden cardiac death or long syndrome
  • Any current or prior history of symptomatic coronary disease (myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, or cardiac anginal chest pain) within 6 months before Screening
  • Cerebrovascular accident within 3 months before Screening
  • Prior exposure to sotatercept or luspatercept or has had an allergic reaction to any of their
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Children ≥1 to <18 years old

    Participants will receive a subcutaneous (SC) injection every 3 weeks (Q3W) of 0.3 mg/kg. Dosage may be adjusted based on protocol-specific guidelines.

    Drug: Sotatercept

Interventions

  • SC injection every 3 weeks (Q3W) of 0.3 mg/kg. Dosage may be adjusted based on protocol-specific guidelines.

    Also known as: MK-7962

06

What researchers measure

Primary outcomes

  1. Serum Trough Concentration (Ctrough) of Sotatercept

    Ctrough was the lowest concentration of Sotatercept in serum just before the next dose. Blood samples will be collected at multiple time points to estimate the Ctrough of Sotatercept.

    Time frame: Predose Day 1, Day 21, Day 42, Day 63, Day 84, Day105, Day 126, Day 147, Day 168, Day 189. Postdose Day 7, Day 14, Day 64, Day 69 and Day 76

  2. Area Under the Curve at Steady State (AUCss) of Sotatercept

    Blood samples will be collected at multiple time points to estimate the AUCss of Sotatercept.

    Time frame: Predose Day 1, Day 21, Day 42, Day 63, Day 84, Day105, Day 126, Day 147, Day 168, Day 189. Postdose Day 7, Day 14, Day 64, Day 69 and Day 76

  3. Area Under the Curve from 0 to 3 weeks (AUC0-3 weeks) of Sotatercept

    Blood samples will be collected at Predose Day 1, Day 7, Day 14, and Predose Day 21 to estimate the AUC0-3 weeks of Sotatercept.

    Time frame: Predose Day 1, Day 7, Day 14, and Predose Day 21

  4. Percentage of Participants Who Experience at Least 1 Adverse Event (AE)

    An AE is any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The percentage of participants with 1 or more AEs will be assessed.

    Time frame: Up to 24 weeks

  5. Percentage of Participants Who Discontinue Study Drug Due to an AE

    An AE is any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. The percentage of participants who discontinued the study drug due to an AE regardless of study completion status will be assessed.

    Time frame: Up to 24 weeks

  6. Laboratory Parameter (Hematology): Concentration of Hemoglobin

    Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The concentration of hemoglobin will be presented.

    Time frame: Up to 24 weeks

  7. Laboratory Parameter (Hematology): Hematocrit

    Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The hematocrit will be presented.

    Time frame: Up to 24 weeks

  8. Laboratory Parameter (Hematology): Red Blood Cell (RBC) Count

    Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The RBC count will be presented.

    Time frame: Up to 24 weeks

  9. Laboratory Parameter (Hematology): Reticulocyte Count

    Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The reticulocyte count will be presented.

    Time frame: Up to 24 weeks

  10. Laboratory Parameter (Hematology): Platelet Count

    Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The platelet count will be presented.

    Time frame: Up to 24 weeks

  11. Blood Pressure (BP)

    BP will be assessed while the participant was seated after a period of rest in a quiet setting with no distractions (eg, television and cell phones).

    Time frame: Up to 24 weeks

  12. Titer of Anti-drug Antibody (ADA) to Sotatercept

    ADA to Sotatercept will be assessed.

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Mean Change from Baseline in 6-Minute Walk Distance (6MWD) (Cohorts 1 and 2)

    6MWD will be assessed using the 6-minute walk test (6MWT).

    Time frame: Baseline and Week 24

  2. Mean Change from Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE)

    A two-dimensional echocardiogram (ECHO) will be performed with the results interpreted by a blinded independent central review (BICR) at baseline and after 24 weeks of treatment. The change from baseline in TAPSE will be reported.

    Time frame: Baseline and Week 24

  3. Mean Change from Baseline in Pulmonary Artery Systolic Pressure (PASP)

    A two-dimensional ECHO will be performed with the results interpreted by a BICR at baseline and after 24 weeks of treatment. The change from baseline in PASP will be reported.

    Time frame: Baseline and Week 24

  4. Mean Change from Baseline in Right Ventricular Fractional Area Change (RVFAC)

    A two-dimensional ECHO will be performed with the results interpreted by a BICR at baseline and after 24 weeks of treatment. The change from baseline in RVFAC will be reported.

    Time frame: Baseline and Week 24

  5. Mean Change from Baseline in Eccentricity Index

    A two-dimensional ECHO will be performed with the results interpreted by a BICR at baseline and after 24 weeks of treatment. The change from baseline in eccentricity index will be reported.

    Time frame: Baseline and Week 24

  6. Mean Change from Baseline in Right Ventricular (RV) Function (Cohorts 1 and 2)

    Cardiac magnetic imaging (MRI) will be performed with the results interpreted by a BICR at baseline and after 24 weeks of treatment. The change from baseline in eccentricity index will be reported.

    Time frame: Baseline and Week 24

  7. Mean Change from Baseline on Cardiac Output (Cohorts 1 and 2)

    Cardiac magnetic imaging (MRI) will be performed with the results interpreted by a BICR at baseline and after 24 weeks of treatment. The change from baseline in cardiac output will be reported.

    Time frame: Baseline and Week 24

  8. Mean Change from Baseline in Pulmonary Arterial Pressure (PAP) (Cohorts 1 and 2)

    Cardiac magnetic imaging (MRI) will be performed with the results interpreted by a BICR at baseline and after 24 weeks of treatment. The change from baseline in PAP will be reported.

    Time frame: Baseline and Week 24

  9. Mean Change from Baseline in Pediatric Quality of Life (PedsQL) Generic Score

    PedsQL Measurement Model is a modular approach to measuring health-related quality of life in healthy children and adolescents and those with acute and chronic health conditions. The change from baseline in the PedsQL generic core scale will be reported.

    Time frame: Baseline and Week 24

  10. Mean Change from Baseline in N-terminal Prohormone B-type Natriuretic Peptide (NT-proBNP)

    The change from baseline in plasma NT-proBNP levels will be reported.

    Time frame: Baseline and Week 24

  11. Percentage of Participants Who Either Improved or Maintained Their World Health Organization Functional Class (WHO FC)

    The severity of an individual's PAH symptoms will be graded using the WHO FC system. WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). The change from baseline in WHO FC will be classified into "Improved", "No change" and "Worsened". Improvement = reduction in FC, worsened = increase in FC and no change = no change in FC.

    Time frame: Baseline and Week 24

07

Study locations

34 of 35 sites recruiting
  • The Regents of the University of California - Los Angeles (UCLA Pediatrics) ( Site 1606)
    Los Angeles, California 90095, United States
    Recruiting
    • Study Coordinator · Contact310-267-7667
  • Stanford University School of Medicine ( Site 1603)
    Palo Alto, California 94304, United States
    Recruiting
    • Study Coordinator · Contact650-497-8000
  • UCSF Benioff Children's Hospital San Francisco ( Site 1611)
    San Francisco, California 94158, United States
    Recruiting
    • Study Coordinator · Contact415-476-3831
  • Children's Hospital Colorado ( Site 1609)
    Aurora, Colorado 80045, United States
    Recruiting
    • Study Coordinator · Contact720-777-6427
  • Children's National Medical Center ( Site 1600)
    Washington D.C., District of Columbia 20010, United States
    Recruiting
    • Study Coordinator · Contact202-476-2130
  • Cincinnati Children's Hospital Medical Center ( Site 1602)
    Cincinnati, Ohio 45229, United States
    Recruiting
    • Study Coordinator · Contact513-636-7072
  • Children's Hospital of Philadelphia (CHOP) ( Site 1608)
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
    • Study Coordinator · Contact267-426-0120
  • Monroe Carell Jr. Children's Hospital ( Site 1601)
    Nashville, Tennessee 37232, United States
    Completed

    Not enrolling at this site — choose another above.

  • Seattle Children's Hospital ( Site 1605)
    Seattle, Washington 98105, United States
    Recruiting
    • Study Coordinator · Contact206-987-2000
  • Children's Wisconsin ( Site 1610)
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • Study Coordinator · Contact414-266-2000
  • The Children's Hospital at Westmead ( Site 0001)
    Westmead, New South Wales 2145, Australia
    Recruiting
    • Study Coordinator · Contact+61298452345
  • Clinica Somer-Unidad de Investigacion y Docencia ( Site 0205)
    Rionegro, Antioquia 054040, Colombia
    Recruiting
    • Study Coordinator · Contact+573003358838
  • Fundación Valle del Lili ( Site 0200)
    Cali, Valle del Cauca Department 760032, Colombia
    Recruiting
    • Study Coordinator · Contact+576023319090
  • Clínica Imbanaco S.A.S ( Site 0203)
    Cali, Valle del Cauca Department 760042, Colombia
    Recruiting
    • Study Coordinator · Contact+576023851000
  • CHU de Toulouse - Hôpital des Enfants ( Site 0302)
    Toulouse, Haute-Garonne 31059, France
    Recruiting
    • Study Coordinator · Contact+33534558597
  • Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone ( Site 0303)
    Marseille, Provence-Alpes-Côte d'Azur Region 13005, France
    Recruiting
    • Study Coordinator · Contact+33 4 91 38 67 50
  • Hôpital Universitaire Necker Enfants Malades ( Site 0300)
    Paris, 75015, France
    Recruiting
    • Study Coordinator · Contact+33 1 71 39 66 22
  • Universitaetsklinikum Heidelberg ( Site 0401)
    Heidelberg, Baden-Wurttemberg 69120, Germany
    Recruiting
    • Study Coordinator · Contact+496221564606
  • Klinikum der Universität München Großhadern ( Site 0404)
    München, Bavaria 81337, Germany
    Recruiting
    • Study Coordinator · Contact+4989440072478
  • Medizinische Hochschule Hannover ( Site 0405)
    Hanover, Lower Saxony 30625, Germany
    Recruiting
    • Study Coordinator · Contact+495115329041
  • Schneider Children's Medical Center ( Site 0603)
    Petah Tikva, 4920235, Israel
    Recruiting
    • Study Coordinator · Contact97239376845
  • Sheba Medical Center ( Site 0601)
    Ramat Gan, 5265601, Israel
    Recruiting
    • Study Coordinator · Contact972353080001
  • University Medical Center Groningen ( Site 0900)
    Groningen, 9713 GZ, Netherlands
    Recruiting
    • Study Coordinator · Contact31505612800
  • Centrum Zdrowia Dziecka w Warszawie-Klinika Kardiologii ( Site 1103)
    Warsaw, Masovian Voivodeship 04-730, Poland
    Recruiting
    • Study Coordinator · Contact+48228157370
  • Uniwersyteckie Centrum Kliniczne-Klinika Kardiologii Dziecięcej i Wad Wrodzonych Serca ( Site 1102)
    Gdansk, Pomeranian Voivodeship 80-952, Poland
    Recruiting
    • Study Coordinator · Contact48583492870
  • Wits Clinical Research-Chris Hani Baragwanath Hospital ( Site 1201)
    Johannesburg, Soweto, Gauteng 2013, South Africa
    Recruiting
    • Study Coordinator · Contact011 983 6501
  • Hospital Universitario Ramón y Cajal ( Site 1300)
    Madrid, Madrid, Comunidad de 28034, Spain
    Recruiting
    • Study Coordinator · Contact+34 913369027
  • Hospital Universitari i Politecnic La Fe ( Site 1303)
    Valencia, Valencia 46026, Spain
    Recruiting
    • Study Coordinator · Contact+34699449273
  • Hospital Universitari Vall d'Hebron ( Site 1302)
    Barcelona, 08035, Spain
    Recruiting
    • Study Coordinator · Contact+34626774330
  • HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 1301)
    Madrid, 28007, Spain
    Recruiting
    • Study Coordinator · Contact+34 915290267
  • Hacettepe Universite Hastaneleri ( Site 1400)
    Ankara, 06100, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+90 (312) 305 50 00
  • Gazi University Health Research and Application Center Gazi -Çocuk Sağlığı ve Hastalıkları Anabilim ( Site 1402)
    Ankara, 06560, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+903129114848
  • Ankara Bilkent Şehir Hastanesi. ( Site 1403)
    Ankara, 06800, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+903125529999
  • Mehmet Akif Ersoy Research and Training Hospital ( Site 1404)
    Istanbul, 34303, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+90 212 471 80 00
  • Great Ormond Street Hospital For Children NHS Foundation Trust ( Site 1500)
    London, London, City of WC1N 3JH, United Kingdom
    Recruiting
    • Study Coordinator · Contact02074059200
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Sep 2028, 68 months after the start.

Of 28 industry-sponsored phase 2 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 48. This study's planned 68 months is above that.

Counting every sponsor, half of 51 studies reached it within 44 months; a quarter within 26 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2022
First posted
Oct 20, 2022
StartActual
Jan 19, 2023
Primary completionEst.
Sep 21, 2028
CompletionEst.
Sep 21, 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date and site details
1 update, last Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05587712
Responsible party
Sponsor
First posted
Oct 20, 2022
Start date
Jan 19, 2023
Primary completion
Sep 21, 2028 (estimated)
Completion
Sep 21, 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotatercept

Start the discussion